Uracil mustard Disease Interactions

Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression. The use of these drugs may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy. Close clinical monitoring of hematopoietic function is recommended.

The use of uracil mustard has been associated with a dose-related myelosuppression and irreversible bone marrow failure. Therapy with uracil mustard should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy. Uracil mustard should be withheld until white blood cell count exceeds 3,000/mm3 and/or platelet count exceeds 100,000/mm3. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Close clinical monitoring of hematopoietic function is recommended.

The use of uracil mustard is contraindicated in patients with severe leukopenia or thrombocytopenia. Uracil mustard has a cumulative toxic effect against the bone marrow. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. If severe bone marrow suppression occurs, uracil mustard should be discontinued. An accumulated dose of 1 mg/kg is associated with an increased risk of irreversible bone marrow suppression. Close clinical monitoring of hematopoietic function is recommended.